Axsome Therapeutics AXSM Income Statement (2015-2026)

NASDAQ AXSM
$206.49 -1.87 (-0.90%)
As of: Sep 4, 2026 · 1:34 PM EDT
Reported Financials

Axsome Therapeutics Quarterly Income Statement

Periods 46 quarters
Latest Jun 2026

Axsome Therapeutics reported revenue of $218.38M and net income of -$51.31M for the quarter ended Jun 2026, up 45.5% year over year. This income statement covers 46 quarters of results from Mar 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue
8.82M16.85M24.37M94.58M46.70M57.79M71.53M75.00M87.17M104.76M0.50M121.46M150.04M170.99M196.00M191.20M218.38M
Cost of RevenueCost of Rev
0.98M1.92M2.29M7.56M4.60M6.53M7.38M6.30M8.05M8.44M10.51M9.79M13.45M11.91M12.33M14.72M13.56M
Gross Profit
7.84M14.92M22.08M87.02M42.10M51.26M64.15M68.70M79.11M96.33M-10.01M111.67M136.59M159.08M183.67M176.48M204.81M
Operating items
Amortization - Intangibles
0.93M1.61M1.61M1.60M1.59M1.61M1.61M1.59M1.59M1.61M1.61M1.57M1.59M1.61M1.61M1.57M1.59M
Research & DevelopmentR&D
13.18M13.78M12.59M15.79M14.88M14.69M17.79M20.58M28.77M30.80M36.83M49.85M45.39M55.01M44.78M49.54M40.16M2.60M52.68M46.23M
Selling, General & AdministrativeSG&A
20.23M18.83M25.70M31.16M40.89M61.50M74.19M78.94M83.19M86.81M98.97M103.55M95.56M113.27M120.79M130.28M150.24M169.30M185.00M208.14M
Other Operating ExpensesOther Opex
1.05M3.49M8.10M8.97M12.24M7.96M52.19M6.47M11.80M26.43M23.11M12.87M6.93M26.70M51.06M16.89M13.66M
Operating ExpensesOpex
33.41M32.61M38.29M48.00M59.26M84.29M100.95M111.76M119.91M169.80M142.27M165.21M167.39M191.38M178.44M186.76M217.10M222.96M254.56M268.02M
Operating IncomeOp. Inc
-33.41M-32.61M-38.29M-39.18M-42.41M-59.92M-6.37M-65.06M-62.12M-98.27M-67.28M-78.05M-62.62M-72.62M-56.98M-36.71M-46.11M-26.96M-63.36M-49.65M
EBIT
-33.41M-32.61M-38.29M-39.18M-42.41M-59.92M-6.37M-65.06M-62.12M-98.27M-67.28M-78.05M-62.62M-72.62M-56.98M-36.71M-46.11M-26.96M-63.36M-49.65M
Non-operating items
Interest & Investment IncomeInt & Inv Inc
-1.48M-1.37M-1.34M-2.26M-2.41M-1.32M-2.26M-2.73M-0.76M-0.70M-1.08M-1.30M-1.98M-2.21M-2.43M-1.83M-1.12M-1.17M-1.19M-1.54M
Other Non Operating IncomeOther Non Op Inc.
-10.38M
Net income details
EBT
-34.88M-33.98M-39.63M-41.44M-44.82M-61.24M-8.64M-67.79M-62.88M-98.98M-68.36M-79.34M-64.60M-74.83M-59.41M-48.93M-47.23M-28.13M-64.54M-51.19M
Tax ProvisionsTaxes
2.60M-0.62M-0.70M-0.34M0.09M-1.00M-37.48M0.13M
Profit After TaxPAT
-34.88M-33.98M-39.63M-41.44M-44.82M-61.24M-11.22M-67.17M-62.20M-98.65M-68.36M-79.34M-64.60M-74.91M-59.41M-47.97M-47.23M-28.56M-64.54M-51.31M
Income from Continuing OperationsIncome (Continuing)
-34.88M-33.98M-39.63M-41.44M-44.82M-61.24M-11.24M-67.17M-62.18M-98.64M-68.36M-79.34M-64.60M-74.91M-59.41M-47.93M-47.23M9.35M-64.54M-51.31M
Consolidated Net IncomeConsol Net Inc.
-34.88M-33.98M-39.63M-41.44M-44.82M-61.24M-11.24M-67.17M-62.18M-98.64M-68.36M-79.34M-64.60M-74.91M-59.41M-47.93M-47.23M9.35M-64.54M-51.31M
Income towards Parent CompanyParent Net Inc
-34.88M-33.98M-39.63M-41.44M-44.82M-61.24M-11.24M-67.17M-62.18M-98.64M-68.36M-79.34M-64.60M-74.91M-59.41M-47.93M-47.23M9.35M-64.54M-51.31M
Net Income towards Common StockholdersNet Income
-34.88M-33.98M-39.63M-41.44M-44.82M-61.24M-11.24M-67.17M-62.18M-98.64M-68.36M-79.34M-64.60M-74.91M-59.41M-47.93M-47.23M9.35M-64.54M-51.31M
Additional items
EPS (Basic)
-0.93-0.90-1.03-1.06-1.07-1.51-0.26-1.54-1.32-2.17-1.44-1.67-1.34-1.56-1.22-0.97-0.940.19-1.26-0.99
EPS (Diluted)
-0.93-0.90-1.03-1.06-1.07-1.51-0.26-1.54-1.32-2.17-1.44-1.67-1.34-1.56-1.22-0.97-0.940.19-1.26-0.99
Shares Outstanding
37.68M37.62M38.32M39.08M41.70M40.66M43.52M43.67M47.12M45.43M47.39M47.57M48.14M47.91M48.87M49.44M50.02M49.75M51.20M51.80M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
37.68M37.62M38.32M39.08M41.70M40.66M43.52M43.67M47.12M45.43M47.39M47.57M48.14M47.91M48.87M49.44M50.02M49.75M51.20M51.80M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
37.69M37.82M38.88M39.91M43.43M43.50M43.55M46.73M47.32M47.35M47.46M47.80M48.44M48.67M49.22M49.82M50.31M50.88M51.42M52.30M
EBITDA
-33.41M-32.61M-38.29M-39.18M-42.41M-59.92M-6.37M-65.06M-62.12M-98.27M-67.28M-78.05M-62.62M-72.62M-56.98M-36.71M-46.11M-26.96M-63.36M-49.65M
Tax Rate
-30.10%0.91%1.11%0.34%-0.11%2.04%133.24%-0.25%